Contact Us

Get 30% Free Customization on This Report

Published Date: June, 2019

Acetazolamide Market (Dosage Form - Injection, Capsules, and Tablets; Disease - Glaucoma, Epilepsy, Altitude Sickness, Periodic Paralysis, Idiopathic Intracranial Hypertension, Heart Failure, and Other Diseases; Distribution Channel - Hospital, Retail Drug Store, and Online Drug Store): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025


Request Discount Enquire Before Buying

A recent report published by Infinium Global Research on acetazolamide market provides in-depth analysis of segments and sub-segments in the global as well as regional acetazolamide market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional acetazolamide market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global acetazolamide market. According to the report, the global acetazolamide market is projected to grow at a CAGR of 4.1% over the forecast period of 2019-2025.


Global Acetazolamide Market

 

Market Insight

Acetazolamide is a carbonic anhydrase(CA) inhibitor, works to cause the accumulation of carbonic acid by preventing its breakdown. It works to absorb chloride, bicarbonate, and sodium to make blood more acidic. It is used to treat a large number of the disease such as glaucoma, periodic paralysis, heart failure, altitude sickness, epilepsy, idiopathic intracranial hypertension, and many others. It is an important remedy to treat high altitudes related problems such as AMS (Acute Motion Sickness), HAPE (High Altitude Pulmonary Edema) and HACE (High Altitude Cerebral Edema). During the treatment of high altitude related problems, it inhibits the carbonic anhydrase enzymes, which helps to excretion of bicarbonate in the urine. Aftermath, it hastens the acclimatization and removes high altitude disorders. Further, acetazolamide is the first generation CA inhibitors(CAIs) used for the treatment of the glaucoma disease. It is used as a systematic drug to treat glaucoma. It is used singly or in combination with other drugs as adrenergic agonist/antagonist, to treat the glaucoma problem.

 

The growing prevalence of glaucoma, periodic paralysis, heart failure, altitude sickness, epilepsy, idiopathic intracranial hypertension, and other diseases are expected to boost the demand of the acetazolamide around the world. But, some side effects owing to excessive application of the acetazolamide such as dizziness, lightheadedness, frequent urinating during the medication, vomiting are forcing the consumers to use other alternatives of acetazolamide. However, its growing availability as generic medicine around the world and no effective alternatives for several diseases as altitude sickness is expected to boost the growth of the market in the near future. Additionally, its low price factor owning to its generic medicine category is helping to grow its market around the world. Further, growing innovation in the introduction of different type of acetazolamide based product in the potential market is helping to grow the demand for this medicine. Recently, Zydus Cadila got final approval from USFDA to market acetazolamide based injection USP, 500 mg per single dose vial in around the globe. This new product launch is expected to boost the demand for acetazolamide injection among developed and developing countries.

 

Among the regions, Asia-Pacific is the largest market of the acetazolamide products, owing to the availability of several drug manufacturing companies in this region. Additionally, availability of the large patient pool for several diseases, and government support to provide basic medicine at the low price is boosting the demand of the acetazolamide products in this region. The North America and Europe are following the Asia-Pacific market.    

 

Segment Covered

The report on global acetazolamide market covers segments such as dosage form, disease, and distribution channel. On the basis of dosage form, the sub-markets include injection, capsules, and tablets. On the basis of disease, the sub-markets include glaucoma, epilepsy, altitude sickness, periodic paralysis, idiopathic intracranial hypertension, heart failure, and other diseases. On the basis of distribution channel, the sub-markets include hospital, retail drug store, and online drug store.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Emcure Pharmaceuticals Limited, Mylan N.V., X-Gen Pharmaceuticals, Inc, West-Ward Pharmaceutical Corp., Strides Pharma Science Limited(Strides), Nostrum Laboratories Inc, Heritage Pharmaceuticals, Sun Pharmaceutical Industries Limited, Lannett Co Inc, and Zydus Pharmaceuticals (USA) Inc.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of acetazolamide market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. 

The Infinium Advantages

Analyst Support

Get free analyst support for the queries before and post purchasing report.

Customer Satisfaction

Be assured of 100% customer satisfaction about the research and get 24X7 customer support.

400% Growth

Infinium has achieved over 400%+ growth in its repository and revenue over the last 2 years. Yes, we are proud to say we are growing at a great pace and becoming a trusted partner among our clients.

Related Reports

sign up for our newsletter